IVIG in Immunocompromised Pediatric Patients - Advances and Prospects?

Abstract

Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology